{"adverse_reactions":["6 ADVERSE REACTIONS The most commonly reported adverse reactions are headache (1.8%) and nausea (1.6%). (6) To report SUSPECTED ADVERSE REACTIONS, contact Bracco Diagnostics Inc. at 1-800-257-8151 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adult In clinical trials, a total of 2982 adult subjects (119 healthy volunteers and 2863 patients) received MultiHance at doses ranging from 0.005 to 0.4 mmol/kg. There were 1724 (58%) men and 1258 (42%) women with a mean age of 55.1 years (range 18 to 92 years). A total of 2644 (89%) subjects were Caucasian, 84 (3%) Black, 162 (5%) Asian, 29 (1%) Hispanic, 18 (1%) in other racial groups, and for 45 (2%) subjects, race was not reported. The most commonly reported adverse reactions in adult subjects who received MultiHance were headache (1.8%) and nausea (1.6%). Most adverse reactions were mild to moderate in intensity. Four subjects experienced serious adverse reactions. One subject with a history of seizures experienced convulsions 17 minutes after the administration of MultiHance. Another subject with a history of recent myocardial infarction (MI) and congestive heart failure (CHF) experienced acute pulmonary edema within 10 minutes after the administration of 30 mL of MultiHance. The third subject developed acute necrotizing pancreatitis. The fourth subject experienced an anaphylactoid reaction with laryngismus and dyspnea [ see Warnings and Precautions (5.1) ]. Adverse reactions that occurred in at least 0.5% of 2982 adult subjects who received MultiHance are listed below (Table 1), in decreasing order of occurrence within each system. TABLE 1: ADVERSE REACTIONS REPORTED IN ≥ 0.5% OF ADULT SUBJECTS WHO RECEIVED MultiHance IN CLINICAL TRIALS Number of subjects dosed 2982 Number of subjects with any adverse reaction 450 (15.1%) Gastrointestinal Disorders Nausea 48 (1.6%) Vomiting 14 (0.5%) General Disorders and Administration Site Disorders Feeling Hot 31 (1.0%) Injection Site Reaction 40 (1.3%) Nervous System Disorders Headache 54 (1.8%) Taste perversion 25 (0.8%) Paresthesia 23 (0.8%) Dizziness 22 (0.7%) Skin and Subcutaneous Tissue Disorders Rash 19 (0.6%) Vascular Disorders Hypertension 16 (0.5%) The following adverse reactions occurred in less than 0.5% of the 2982 adult subjects who received MultiHance: Blood and Lymphatic System Disorders: Basophilia, decreased hemoglobin, hemolysis, leukocytosis, leukopenia; Cardiac Disorders: Arrhythmia, atrial fibrillation, bradycardia, chest discomfort, ECG abnormality (bundle branch block, complete AV block, first-degree AV block, inverted T wave, prolonged PR interval, prolonged QT interval, shortened QT interval), myocardial ischemia, palpitations, supraventricular extrasystoles, tachycardia, ventricular arrhythmia, ventricular extrasystoles; Ear and Labyrinth Disorders: Ear pain, tinnitus; Eye Disorders: Eyelid edema, ocular hyperemia, visual disturbance; Gastrointestinal Disorders: Acute necrotizing pancreatitis, abdominal pain, constipation, diarrhea, dry mouth, dyspepsia, fecal incontinence, increased pruritus in patients with cirrhosis, vomiting; General Disorders and Administration Site Conditions: Asthenia, back pain, chest pain, chills, fever, infection, injection site extravasation, injection site inflammation, injection site pain, malaise, rigors; Immune System Disorders: Anaphylactic and anaphylactoid reactions, anaphylactic shock, hypersensitivity reactions; Investigations: Abnormal laboratory test (includes changes in CPK, creatinine, ferritin, transferrin, total iron binding capacity), bilirubinemia, hyperglycemia, hyperkalemia, hypocalcemia, hypoglycemia, hyponatremia, decreased blood albumin, increased alkaline phosphatase, increased GGT, increased LDH, increased serum iron, increased SGOT, increased SGPT; Musculoskeletal and Connective Tissue Disorders: Muscle spasms, myalgia, myositis; Nervous System Disorders: Aphasia, convulsion, hemiplegia, hypertonia, hypoesthesia, paralysis, parosmia, stupor, syncope, tremor; Renal and Urinary Disorders: Albuminuria, glycosuria, hematuria, proteinuria, urinary frequency, urinary tract infection; Respiratory, Thoracic and Mediastinal Disorders: Acute pulmonary edema, cough, dyspnea, hyperventilation, laryngospasm, nasal congestion, obstructive airway disorder, pulmonary embolus, wheezing; Skin and Subcutaneous Tissue Disorders: Facial edema, hyperhidrosis, pruritus, sweating, urticaria; Vascular Disorders: Hypotension. Pediatric In clinical trials, 217 pediatric subjects received MultiHance at a dose of 0.1 mmol/kg. A total of 112 (52%) subjects were male and the overall mean age was 8.3 years (range 4 days to 17 years). A total of 168 (77%) subjects were Caucasian, 12 (6%) Black, 12 (6%) Asian, 24 (11%), Hispanic, and 1 (<1%) in other racial groups. Adverse reactions were reported for 14 (6.5%) of the subjects. The frequency and the nature of the adverse reactions were similar to those seen in the adult patients. The most commonly reported adverse reactions were vomiting (1.4%), pyrexia (0.9%), and hyperhidrosis (0.9%). No subject died during study participation. A serious adverse reaction of worsening of vomiting was reported for one (0.5%) patient with a brain tumor (glioma) for which a causal relationship to MultiHance could not be excluded. 6.2 Post-marketing Experience The following adverse reactions have been identified during post approval use of MultiHance. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Anaphylactic, anaphylactoid and hypersensitivity reactions manifested with various degrees of severity up to anaphylactic shock, loss of consciousness and death. The reactions generally involved signs or symptoms of respiratory, cardiovascular, and/or mucocutaneous abnormalities. Extravasation of MultiHance may lead to injection site reactions, characterized by local pain or burning sensation, swelling, blistering, and necrosis [ see Warnings and Precautions (5.4) ]."],"adverse_reactions_table":["
TABLE 1: ADVERSE REACTIONS REPORTED IN ≥ 0.5% OF ADULT SUBJECTS WHO RECEIVED MultiHance IN CLINICAL TRIALS
Number of subjects dosed 2982
Number of subjects with any adverse reaction 450 (15.1%)
Gastrointestinal Disorders
Nausea 48 (1.6%)
Vomiting 14 (0.5%)
General Disorders and Administration Site Disorders
Feeling Hot 31 (1.0%)
Injection Site Reaction 40 (1.3%)
Nervous System Disorders
Headache 54 (1.8%)
Taste perversion 25 (0.8%)
Paresthesia 23 (0.8%)
Dizziness 22 (0.7%)
Skin and Subcutaneous Tissue Disorders
Rash 19 (0.6%)
Vascular Disorders
Hypertension 16 (0.5%)
"],"boxed_warning":["WARNING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with: acute or chronic severe renal insufficiency (glomerular filtration rate <30 mL/min/1.73m 2 ), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period. In these patients, avoid use of gadolinium-based contrast agents unless the diagnostic information is essential and not available with non-contrast enhanced magnetic resonance imaging (MRI). NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs. Screen all patients for renal dysfunction by obtaining a history and/or laboratory tests. When administering a gadolinium-based contrast agent, do not exceed the recommended dose and allow a sufficient period of time for elimination of the agent from the body prior to any readministration [ see Warnings and Precautions (5.2) ]. WARNING: NEPHROGENIC SYSTEMIC FIBROSIS See full prescribing information for complete boxed warning Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with: acute or chronic severe renal insufficiency (glomerular filtration rate <30 mL/min/1.73m 2 ), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period. In these patients, avoid use of gadolinium-based contrast agents unless the diagnostic information is essential and not available with non-contrast enhanced magnetic resonance imaging (MRI). NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs (5.2) ."],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term animal studies have not been performed to evaluate the carcinogenic potential of MultiHance. The results for MultiHance were negative in the following genetic toxicity studies: 1) in vitro bacteria reverse mutation assays, 2) an in vitro gene mutation assay in mammalian cells, 3) an in vitro chromosomal aberration assay, 4) an in vitro unscheduled DNA synthesis assay, and 5) an in vivo micronucleus assay in rats. MultiHance had no effect on fertility and reproductive performance at IV doses of up to 2 mmol/kg/day (3 times the human dose on body surface basis) for 13 weeks in male rats and for 32 days in female rats. However, vacuolation in testes and abnormal spermatogenic cells were observed when MultiHance was intravenously administered to male rats at 3 mmol/kg/day (5 times the human dose on body surface basis) for 28 days. The effects were not reversible following 28-day recovery period. The effects were not reported in dog and monkey studies (at doses up to about 11 and 10 times the human dose on body surface basis for dogs (28 days dosing) and monkeys (14 days dosing), respectively)."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Gadobenate dimeglumine is a paramagnetic agent and, as such, develops a magnetic moment when placed in a magnetic field. The large magnetic moment produced by the paramagnetic agent results in a large local magnetic field, which can enhance the relaxation rates of water protons in its vicinity leading to an increase of signal intensity (brightness) of tissue. In magnetic resonance imaging (MRI), visualization of normal and pathological tissue depends in part on variations in the radiofrequency signal intensity that occur with 1) differences in proton density; 2) differences of the spin-lattice or longitudinal relaxation times (T1); and 3) differences in the spin-spin or transverse relaxation time (T2). When placed in a magnetic field, gadobenate dimeglumine decreases the T1 and T2 relaxation time in target tissues. At recommended doses, the effect is observed with greatest sensitivity in the T1-weighted sequences. 12.2 Pharmacodynamics Unlike other tested paramagnetic contrast agents (See Table 2), MultiHance demonstrates weak and transient interactions with serum proteins that causes slowing in the molecular tumbling dynamics, resulting in strong increases in relaxivity in solutions containing serum proteins. The improved relaxation effect can contribute to increased contrast-to-noise ratio and lesion-to-brain ratio, which may improve visualization. TABLE 2: RELAXIVITY (mM- 1 s- 1 ) OF GADOLINIUM CHELATES r 1 and r 2 relaxivities indicate the efficiency in shortening T1 and T2 relaxation times, respectively. 1 In heparinized human plasma, at 39°C. 2 In citrated human plasma, at 37°C. -- Not available Human plasma r 1 r 2 Gadobenate 9.7 1 12.5 1 Gadopentetate 4.9 1 6.3 1 Gadodiamide 5.4 2 -- Gadoteridol 5.4 2 -- MultiHance injection does not cross the intact blood-brain barrier and, therefore, does not enhance normal brain or lesions that have a normal blood-brain barrier, e.g., cysts, mature post-operative scars. However, disruption of the blood-brain barrier or abnormal vascularity allows enhancement by MultiHance of lesions such as neoplasms, abscesses, and infarcts. Uptake of MultiHance into hepatocytes has been demonstrated. 12.3 Pharmacokinetics Three single-dose intravenous studies were conducted in 32 healthy male subjects to assess the pharmacokinetics of gadobenate dimeglumine. The doses administered in these studies ranged from 0.005 to 0.4 mmol/kg. Upon injection, the meglumine salt is completely dissociated from the gadobenate dimeglumine complex. Thus, the pharmacokinetics is based on the assay of gadobenate ion, the MRI contrast effective ion in gadobenate dimeglumine. Data for plasma concentration and area under the curve demonstrated linear dependence on the administered dose. The pharmacokinetics of gadobenate ion following intravenous administration can be best described using a two-compartment model. Distribution Gadobenate ion has a rapid distribution half-life (reported as mean ± SD) of 0.084 ± 0.012 to 0.605 ± 0.072 hours. Volume of distribution of the central compartment ranged from 0.074 ± 0.017 to 0.158 ± 0.038 L/kg, and estimates of volume of distribution by area ranged from 0.170 ± 0.016 to 0.282 ± 0.079 L/kg. These latter estimates are approximately equivalent to the average volume of extracellular body water in man. In vitro studies showed no appreciable binding of gadobenate ion to human serum proteins. Elimination Gadobenate ion is eliminated predominately via the kidneys, with 78% to 96% of an administered dose recovered in the urine. Total plasma clearance and renal clearance estimates of gadobenate ion were similar, ranging from 0.093 ± 0.010 to 0.133 ± 0.270 L/hr/kg and 0.082 ± 0.007 to 0.104 ± 0.039 L/hr/kg, respectively. The clearance is similar to that of substances that are subject to glomerular filtration. The mean elimination half-life ranged from 1.17 ± 0.26 to 2.02 ± 0.60 hours. A small percentage of the administered dose (0.6% to 4%) is eliminated via the biliary route and recovered in feces. Metabolism There was no detectable biotransformation of gadobenate ion. Dissociation of gadobenate ion in vivo has been shown to be minimal, with less than 1% of the free chelating agent being recovered alone in feces. Pharmacokinetics in Special Population Renal Impairment: A single intravenous dose of 0.2 mmol/kg of MultiHance was administered to 20 subjects with impaired renal function (6 men and 3 women with moderate renal impairment [urine creatinine clearance >30 to <60 mL/min] and 5 men and 6 women with severe renal impairment [urine creatinine clearance >10 to <30 mL/min]). Mean estimates of the elimination half-life were 6.1 ± 3.0 and 9.5 ± 3.1 hours for the moderate and severe renal impairment groups, respectively as compared with 1.0 to 2.0 hours in healthy volunteers. Hemodialysis: A single intravenous dose of 0.2 mmol/kg of MultiHance was administered to 11 subjects (5 males and 6 females) with end-stage renal disease requiring hemodialysis to determine the pharmacokinetics and dialyzability of gadobenate. Approximately 72% of the dose was recovered by hemodialysis over a 4-hour period. The mean elimination half-life on dialysis was 1.21 ± 0.29 hours as compared with 42.4 ± 24.4 hours when off dialysis. Hepatic Impairment: A single intravenous dose of 0.1 mmol/kg of MultiHance was administered to 11 subjects (8 males and 3 females) with impaired liver function (Class B or C modified Child-Pugh Classification). Hepatic impairment had little effect on the pharmacokinetics of MultiHance with the parameters being similar to those calculated for healthy subjects. Gender, Age, Race: A multiple regression analysis performed using pooled data from several pharmacokinetic studies found no significant effect of sex upon the pharmacokinetics of gadobenate. Clearance appeared to decrease slightly with increasing age. Since variations due to age appeared marginal, dosage adjustment for geriatric population is not recommended. Pharmacokinetic differences due to race have not been systematically studied. Pediatric: A population pharmacokinetic analysis incorporated data from 25 healthy subjects (14 males and 11 females) and 15 subjects undergoing MR imaging of the central nervous system (7 males and 8 females) between ages of 2 and 16 years. The subjects received a single intravenous dose of 0.1 mmol/kg of MultiHance. The geometric mean C max was 62.3 μg/mL (n=16) in children 2 to 5 years of age, and 64.2 μg/mL (n=24) in children older than 5 years. The geometric mean AUC 0-∞ was 77.9 μg-h/mL in children 2-5 years of age (n=16) and 82.6 μg-h/mL in children older than 5 years (n=24). The geometric mean half-life was 1.2 hours in children 2 to 5 years of age and 0.93 hours in children older than 5 years. There was no significant gender-related difference in the pharmacokinetic parameters in the pediatric patients. Over 80% of the dose was recovered in urine after 24 hours."],"clinical_pharmacology_table":["
TABLE 2: RELAXIVITY (mM-1s-1) OF GADOLINIUM CHELATES
r1 and r2 relaxivities indicate the efficiency in shortening T1 and T2 relaxation times, respectively. 1 In heparinized human plasma, at 39°C. 2 In citrated human plasma, at 37°C. -- Not available
Human plasma
r1 r2
Gadobenate 9.71 12.51
Gadopentetate 4.91 6.31
Gadodiamide 5.42 --
Gadoteridol 5.42 --
"],"clinical_studies":["14 CLINICAL STUDIES MultiHance was evaluated in 426 adult patients in 2 controlled clinical trials of the central nervous system (Study A and Study B), enrolling 217 men and 209 women with a mean age of 52 years (range 18 to 88 years). The racial and ethnic representations were 88% Caucasian, 6% Black, 4% Hispanic, 1% Asian, and 1% other racial or ethnic groups. These trials were designed to compare MultiHance contrast MRI to non-contrast MRI alone. In Study A, patients highly suspected of having a lesion(s) of the CNS based on nuclear medicine imaging, computed tomography (CT), contrast CT, MRI, contrast- MRI, or angiography were randomized to receive two MRI evaluations with 0.05 mmol/kg (n=140) or 0.1 mmol/kg (n=136) of MultiHance. In Study B, patients with known metastatic disease to the CNS were randomized to receive two MRI evaluations with 0.05 mmol/kg (n=74) or 0.1 mmol/kg (n=76) of MultiHance. MRI scans were performed pre-contrast and within 5 minutes after each injection. The studies were designed to evaluate the effect of MultiHance MRI compared to the non-contrast MRI on a lesion level. Pre-contrast, post-contrast, and pre-plus-post contrast images (paired images) were independently evaluated by three blinded readers. The images were evaluated for the following endpoints using a scale from 0 to 4: the degree of lesion border delineation, the degree of visualization of lesion internal morphology, and the degree of lesion contrast enhancement. Lesion counting was also performed for the pre-contrast and paired image sets. The 0.1 mmol/kg dose of MultiHance demonstrated consistently better visualization for all readers for all visualization endpoints. However, the 0.05 mmol/kg dose of MultiHance provided inconsistent visualization results between readers. Comparison of pre-contrast versus post-contrast (0.1 mmol/kg) images showed that the mean score differences were significant and favored contrast for subjects in Study B (all subjects with known metastatic lesions) and for subjects with known tumors in Study A. However, the mean score differences between the pre-contrast and post-contrast images were not significant for non-tumor patients in Study A. These negative results may be attributed to a lack of lesion enhancement in non-tumor CNS disease. Table 3 shows a comparison of paired images (pre-and post-contrast) versus pre-contrast images with respect to the difference in the mean score and with respect to the proportion of lesions read as better, worse, or the same as the pre-contrast MRI images. Table 3 shows that based on a lesion-level analysis 0.1 mmol/kg MultiHance provided a statistically significant improvement for the three structural parameters evaluated. Also, more lesions were seen in the paired images than in the pre-contrast images alone. Table 3: LESION LEVEL RESULTS OF MRI CENTRAL NERVOUS SYSTEM ADULT STUDIES WITH 0.1 mmol/kg MultiHance (a) Difference of means = (paired mean) - (pre mean) (b) Worse = paired score is less than the pre score Same = paired score is the same as the pre score Better = paired score is greater than the pre score * Statistically significant for the mean (paired t test) Study A Study B Reader 1 Reader 2 Reader 3 Reader 1 Reader 2 Reader 3 Endpoints N = 395 N = 384 N = 299 N = 245 N = 275 N = 254 Border Delineation: Difference of Means (a) 0.8* 0.6* 0.8* 1.8* 1.5* 1.9* Worse (b) Same Better 44 (11%) 146 (37%) 205 (52%) 61 (16%) 168 (44%) 155 (40%) 57 (19%) 89 (30%) 153 (51%) 13 (5%) 11 (5%) 221 (90%) 24 (9%) 19 (7%) 232 (84%) 15 (6%) 18 (7%) 221 (87%) Internal Morphology: Difference of Means 0.8* 0.6* 0.7* 1.7* 1.4* 2.1* Worse Same Better 37 (10%) 147 (37%) 211 (53%) 63 (17%) 151 (39%) 170 (44%) 62 (21%) 84 (28%) 153 (51%) 13 (5%) 16 (7%) 216 (88%) 26 (10%) 22 (8%) 227 (82%) 14 (5%) 22 (9%) 218 (86%) Contrast Enhancement: Difference of Means 0.7* 0.5* 0.8* 1.9* 1.3* 1.9* Worse Same Better 75 (19%) 148 (37%) 172 (44%) 74 (19%) 152 (40%) 158 (41%) 50 (17%) 109 (36%) 140 (47%) 13 (5%) 11 (5%) 221 (90%) 32 (12%) 21 (7%) 222 (81%) 17 (7%) 14 (5%) 223 (88%) The efficacy and safety of MultiHance were evaluated in 92 pediatric patients with known or highly suspected disease of the central nervous system. MRI scans were performed pre-contrast and within 3 to 10 minutes following the administration of MultiHance 0.1 mmol/kg. Pre-contrast, post-contrast, and pre-plus-post contrast images (paired images) were independently evaluated by three blinded readers on a lesion level. The images were evaluated for the same endpoints as in the adult central nervous system trials using a scale from 0 to 4: the degree of lesion border delineation, the degree of visualization of lesion internal morphology, and the degree of lesion contrast enhancement. Lesion counting was also performed for the pre-contrast and paired image sets. The pre-contrast versus the paired image set was the primary comparison. Forty-nine percent of study subjects were male and the overall mean age was 10.6 years (range 2 to 17 years). The racial and ethnic representations were 77% Caucasian, 13% Asian, 5% Black, and 4% other racial or ethnic groups. MultiHance increased lesion border delineation, lesion internal morphology, and lesion contrast enhancement relative to non-contrast and these results were comparable to those seen in adults."],"clinical_studies_table":["
Table 3: LESION LEVEL RESULTS OF MRI CENTRAL NERVOUS SYSTEM ADULT STUDIES WITH 0.1 mmol/kg MultiHance
(a) Difference of means = (paired mean) - (pre mean) (b) Worse = paired score is less than the pre score Same = paired score is the same as the pre score Better = paired score is greater than the pre score * Statistically significant for the mean (paired t test)
Study A Study B
Reader 1 Reader 2 Reader 3 Reader 1 Reader 2 Reader 3
Endpoints N = 395 N = 384 N = 299 N = 245 N = 275 N = 254
Border Delineation:
Difference of Means (a) 0.8* 0.6* 0.8* 1.8* 1.5* 1.9*
Worse (b) Same Better 44 (11%) 146 (37%) 205 (52%) 61 (16%) 168 (44%) 155 (40%) 57 (19%) 89 (30%) 153 (51%) 13 (5%) 11 (5%) 221 (90%) 24 (9%) 19 (7%) 232 (84%) 15 (6%) 18 (7%) 221 (87%)
Internal Morphology:
Difference of Means 0.8* 0.6* 0.7* 1.7* 1.4* 2.1*
Worse Same Better 37 (10%) 147 (37%) 211 (53%) 63 (17%) 151 (39%) 170 (44%) 62 (21%) 84 (28%) 153 (51%) 13 (5%) 16 (7%) 216 (88%) 26 (10%) 22 (8%) 227 (82%) 14 (5%) 22 (9%) 218 (86%)
Contrast Enhancement:
Difference of Means 0.7* 0.5* 0.8* 1.9* 1.3* 1.9*
Worse Same Better 75 (19%) 148 (37%) 172 (44%) 74 (19%) 152 (40%) 158 (41%) 50 (17%) 109 (36%) 140 (47%) 13 (5%) 11 (5%) 221 (90%) 32 (12%) 21 (7%) 222 (81%) 17 (7%) 14 (5%) 223 (88%)
"],"contraindications":["4 CONTRAINDICATIONS MultiHance is contraindicated in patients with known allergic or hypersensitivity reactions to gadolinium-based contrast agents [ see Warnings and Precautions (5.1) ]. MultiHance is contraindicated in patients with known allergic or hypersensitivity reactions to gadolinium-based contrast agents. (4)"],"description":["11 DESCRIPTION MultiHance injection is supplied as a sterile, nonpyrogenic, clear, colorless, aqueous solution intended for intravenous use only. Each mL of MultiHance contains 529 mg gadobenate dimeglumine and water for injection. MultiHance contains no preservatives. Gadobenate dimeglumine is chemically designated as (4RS)-[4-carboxy-5,8,11-tris(carboxymethyl)- 1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-)] gadolinate(2-) dihydrogen compound with 1-deoxy-1-(methylamino)-D-glucitol (1:2) with a molecular weight of 1058.2 and an empirical formula of C 22 H 28 GdN 3 O 11 • 2C 7 H 17 NO 5 . The structural formula is as follows: MultiHance has a pH of 6.5-7.5. Pertinent physicochemical parameters are provided below: Osmolality 1.970 osmol/kg @ 37°C Viscosity 5.3 mPas @ 37°C Density 1.220 g/mL @ 20°C MultiHance has an osmolality 6.9 times that of plasma (285 mOsmol/kg water) and is hypertonic under conditions of use. MultiHance Structure"],"description_table":["
Osmolality 1.970 osmol/kg @ 37°C
Viscosity 5.3 mPas @ 37°C
Density 1.220 g/mL @ 20°C
"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION The recommended dose of MultiHance is 0.1 mmol/kg (0.2 mL/kg) administered as a rapid bolus intravenous injection. To ensure complete injection of the contrast medium, follow the injection with a saline flush of at least 5 mL. Inspect the MultiHance vial visually for particulate matter and discoloration prior to administration. Do not use the solution if it is discolored or particulate matter is present. Draw MultiHance into a syringe and inject using sterile technique. Do not mix intravenous medications or parenteral nutrition solutions with MultiHance. Do not administer other medications in the same intravenous line with MultiHance. MultiHance vials are intended for single use only. Administer immediately after opening and discard any unused product. The recommended dose of MultiHance is 0.1 mmol/kg (0.2 mL/kg) administered as a rapid bolus intravenous injection. To ensure complete injection of the contrast medium, follow the injection with a saline flush of at least 5 mL. (2)"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS MultiHance is a sterile, nonpyrogenic, clear, colorless, aqueous solution for intravenous use only, containing 529 mg gadobenate dimeglumine per mL. Each mL of MultiHance Injection contains 529 mg gadobenate dimeglumine and is available in single use vials. (3)"],"drug_interactions":["7 DRUG INTERACTIONS 7.1 Transporter-Based Drug-Drug Interactions MultiHance and other drugs may compete for the canalicular multispecific organic anion transporter (MOAT also referred to as MRP2 or ABCC2). Therefore MultiHance may prolong the systemic exposure of drugs such as cisplatin, antracyclines (e.g. doxorubicin, daunorubicin), vinca alkaloids (e.g. vincristine), methotrexate, etoposide, tamoxifen, and paclitaxel. In particular, consider the potential for prolonged drug exposure in patients with decreased MOAT activity (e.g. Dubin Johnson syndrome)."],"effective_time":"20121211","geriatric_use":["8.5 Geriatric Use Of the total number of 2982 adult subjects in clinical studies of MultiHance, 27% were 65 and over. No overall differences in safety or effectiveness were observed between these elderly subjects and the younger subjects. The drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to MultiHance may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function it may be useful to monitor renal function."],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING How Supplied MultiHance (gadobenate dimeglumine) is a clear, colorless solution containing 529 mg gadobenate dimeglumine per mL. MultiHance is supplied in plastic disposable syringes in box of: Five 10 mL fills in single dose 20 mL prefilled syringes (NDC 0270-5164-18) Five 15 mL fills in single dose 20 mL prefilled syringes (NDC 0270-5164-19) Five 20 mL fills in single dose 20 mL prefilled syringes (NDC 0270-5164-20) Storage and Handling Inspect the MultiHance vial visually for particulate matter and discoloration prior to administration. Do not use the solution if it is discolored or particulate matter is present. Do not mix intravenous medications or parenteral nutrition solutions with MultiHance. Do not administer other medications in the same intravenous line with MultiHance because of the potential for chemical incompatibility. Draw MultiHance into a syringe and inject using sterile technique. MultiHance vials are intended for single use only. Administer immediately after opening and discard any unused product. Store at 25°C (77°F), excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. Do not freeze."],"id":"7a0a985e-cb76-9c01-1e79-33357b0e3a72","indications_and_usage":["1 INDICATIONS AND USAGE MultiHance is indicated for intravenous use in magnetic resonance imaging (MRI) of the central nervous system (CNS) in adults and children over 2 years of age to visualize lesions with abnormal blood brain barrier or abnormal vascularity of the brain, spine, and associated tissues. MultiHance is a gadolinium-based contrast agent indicated for intravenous use in magnetic resonance imaging (MRI) of the central nervous system (CNS) in adults and children over 2 years of age to visualize lesions with abnormal blood brain barrier or abnormal vascularity of the brain, spine, and associated tissues. (1)"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION 17.1 Nephrogenic Systemic Fibrosis Patients with impaired renal function who receive repetitive administrations of a gadolinium-containing contrast agent may have an increased risk for the development of nephrogenic systemic fibrosis (NSF), especially if the time interval between the administrations precludes clearance of the previously administered contrast agent from the body. Inform patients of this risk and instruct them to contact their physician or healthcare provider if they develop signs or symptoms of NSF, such as burning, itching, swelling, scaling, hardening and tightening of the skin, red or dark patches on the skin, stiffness in joints with trouble moving, bending or straightening the arms, hands, legs or feet, pain deep in the hip bones or ribs, or muscle weakness. 17.2 Common Adverse Reactions Inform patients that they may experience: reactions along the venous injection site, such as mild and transient burning or pain or feeling of warmth or coldness at the injection site side effects of feeling hot, nausea, and headache 17.3 General Precautions Instruct patients scheduled to receive MultiHance to inform their physician if they: are pregnant or breast feeding have a history of renal disease, heart disease, seizure, asthma or allergic respiratory diseases are taking any medications have any allergies to any of the ingredients of MultiHance. © 2010, Bracco Diagnostics Inc. All rights reserved. Manufactured for Bracco Diagnostics Inc. - Princeton, NJ 08543 By Bracco Imaging S.p.A. - 10010 Colleretto Giacosa (Italy) CI00MR"],"mechanism_of_action":["12.1 Mechanism of Action Gadobenate dimeglumine is a paramagnetic agent and, as such, develops a magnetic moment when placed in a magnetic field. The large magnetic moment produced by the paramagnetic agent results in a large local magnetic field, which can enhance the relaxation rates of water protons in its vicinity leading to an increase of signal intensity (brightness) of tissue. In magnetic resonance imaging (MRI), visualization of normal and pathological tissue depends in part on variations in the radiofrequency signal intensity that occur with 1) differences in proton density; 2) differences of the spin-lattice or longitudinal relaxation times (T1); and 3) differences in the spin-spin or transverse relaxation time (T2). When placed in a magnetic field, gadobenate dimeglumine decreases the T1 and T2 relaxation time in target tissues. At recommended doses, the effect is observed with greatest sensitivity in the T1-weighted sequences."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term animal studies have not been performed to evaluate the carcinogenic potential of MultiHance. The results for MultiHance were negative in the following genetic toxicity studies: 1) in vitro bacteria reverse mutation assays, 2) an in vitro gene mutation assay in mammalian cells, 3) an in vitro chromosomal aberration assay, 4) an in vitro unscheduled DNA synthesis assay, and 5) an in vivo micronucleus assay in rats. MultiHance had no effect on fertility and reproductive performance at IV doses of up to 2 mmol/kg/day (3 times the human dose on body surface basis) for 13 weeks in male rats and for 32 days in female rats. However, vacuolation in testes and abnormal spermatogenic cells were observed when MultiHance was intravenously administered to male rats at 3 mmol/kg/day (5 times the human dose on body surface basis) for 28 days. The effects were not reversible following 28-day recovery period. The effects were not reported in dog and monkey studies (at doses up to about 11 and 10 times the human dose on body surface basis for dogs (28 days dosing) and monkeys (14 days dosing), respectively)."],"nursing_mothers":["8.3 Nursing Mothers It is not known to what extent gadobenate dimeglumine is excreted in human milk. It is known from rat experiments that less than 0.5% of the administered dose is transferred via milk from mother to neonates. Breast-feeding should be discontinued prior to the administration of MultiHance and should not be restarted until at least 24 hours after the administration of MultiHance."],"openfda":{},"overdosage":["10 OVERDOSAGE Clinical consequences of overdosage with MultiHance have not been reported. Treatment of an overdosage should be directed toward support of vital functions and prompt institution of symptomatic therapy. In a Phase 1 clinical study, doses up to 0.4 mmol/kg were administered to patients. MultiHance has been shown to be dialyzable [ see Clinical Pharmacology (12.3) ]."],"package_label_principal_display_panel":["Multihance Injection 10mL NDC 0270-5164-18 Multihance Injection 10mL Multihance Injection 5x 10mL Multihance Injection 5x 10mL","Multihance Injection 15mL NDC 0270-5164-19 Multihance Injection 15mL label Multihance Injection 5x 15mL label Multihance Injection 5x 15mL carton","Multihance Injection 20mL NDC 0270-5164-20 Multihance Injection 20mL Multihance Injection 5x 20mL Multihance Injection 20mL"],"pediatric_use":["8.4 Pediatric Use A total of 217 pediatric subjects (93% of subjects aged 2 years and above) were studied in clinical trials. No overall differences in safety or effectiveness were observed between these pediatric subjects and the adult subjects. The safety and efficacy of MultiHance in neonates and infants (ages 0-2 years) have not been established. The risk of NSF related to gadolinium may be increased in these patients due to their immature kidney function."],"pharmacodynamics":["12.2 Pharmacodynamics Unlike other tested paramagnetic contrast agents (See Table 2), MultiHance demonstrates weak and transient interactions with serum proteins that causes slowing in the molecular tumbling dynamics, resulting in strong increases in relaxivity in solutions containing serum proteins. The improved relaxation effect can contribute to increased contrast-to-noise ratio and lesion-to-brain ratio, which may improve visualization. TABLE 2: RELAXIVITY (mM- 1 s- 1 ) OF GADOLINIUM CHELATES r 1 and r 2 relaxivities indicate the efficiency in shortening T1 and T2 relaxation times, respectively. 1 In heparinized human plasma, at 39°C. 2 In citrated human plasma, at 37°C. -- Not available Human plasma r 1 r 2 Gadobenate 9.7 1 12.5 1 Gadopentetate 4.9 1 6.3 1 Gadodiamide 5.4 2 -- Gadoteridol 5.4 2 -- MultiHance injection does not cross the intact blood-brain barrier and, therefore, does not enhance normal brain or lesions that have a normal blood-brain barrier, e.g., cysts, mature post-operative scars. However, disruption of the blood-brain barrier or abnormal vascularity allows enhancement by MultiHance of lesions such as neoplasms, abscesses, and infarcts. Uptake of MultiHance into hepatocytes has been demonstrated."],"pharmacodynamics_table":["
TABLE 2: RELAXIVITY (mM-1s-1) OF GADOLINIUM CHELATES
r1 and r2 relaxivities indicate the efficiency in shortening T1 and T2 relaxation times, respectively. 1 In heparinized human plasma, at 39°C. 2 In citrated human plasma, at 37°C. -- Not available
Human plasma
r1 r2
Gadobenate 9.71 12.51
Gadopentetate 4.91 6.31
Gadodiamide 5.42 --
Gadoteridol 5.42 --
"],"pharmacokinetics":["12.3 Pharmacokinetics Three single-dose intravenous studies were conducted in 32 healthy male subjects to assess the pharmacokinetics of gadobenate dimeglumine. The doses administered in these studies ranged from 0.005 to 0.4 mmol/kg. Upon injection, the meglumine salt is completely dissociated from the gadobenate dimeglumine complex. Thus, the pharmacokinetics is based on the assay of gadobenate ion, the MRI contrast effective ion in gadobenate dimeglumine. Data for plasma concentration and area under the curve demonstrated linear dependence on the administered dose. The pharmacokinetics of gadobenate ion following intravenous administration can be best described using a two-compartment model. Distribution Gadobenate ion has a rapid distribution half-life (reported as mean ± SD) of 0.084 ± 0.012 to 0.605 ± 0.072 hours. Volume of distribution of the central compartment ranged from 0.074 ± 0.017 to 0.158 ± 0.038 L/kg, and estimates of volume of distribution by area ranged from 0.170 ± 0.016 to 0.282 ± 0.079 L/kg. These latter estimates are approximately equivalent to the average volume of extracellular body water in man. In vitro studies showed no appreciable binding of gadobenate ion to human serum proteins. Elimination Gadobenate ion is eliminated predominately via the kidneys, with 78% to 96% of an administered dose recovered in the urine. Total plasma clearance and renal clearance estimates of gadobenate ion were similar, ranging from 0.093 ± 0.010 to 0.133 ± 0.270 L/hr/kg and 0.082 ± 0.007 to 0.104 ± 0.039 L/hr/kg, respectively. The clearance is similar to that of substances that are subject to glomerular filtration. The mean elimination half-life ranged from 1.17 ± 0.26 to 2.02 ± 0.60 hours. A small percentage of the administered dose (0.6% to 4%) is eliminated via the biliary route and recovered in feces. Metabolism There was no detectable biotransformation of gadobenate ion. Dissociation of gadobenate ion in vivo has been shown to be minimal, with less than 1% of the free chelating agent being recovered alone in feces. Pharmacokinetics in Special Population Renal Impairment: A single intravenous dose of 0.2 mmol/kg of MultiHance was administered to 20 subjects with impaired renal function (6 men and 3 women with moderate renal impairment [urine creatinine clearance >30 to <60 mL/min] and 5 men and 6 women with severe renal impairment [urine creatinine clearance >10 to <30 mL/min]). Mean estimates of the elimination half-life were 6.1 ± 3.0 and 9.5 ± 3.1 hours for the moderate and severe renal impairment groups, respectively as compared with 1.0 to 2.0 hours in healthy volunteers. Hemodialysis: A single intravenous dose of 0.2 mmol/kg of MultiHance was administered to 11 subjects (5 males and 6 females) with end-stage renal disease requiring hemodialysis to determine the pharmacokinetics and dialyzability of gadobenate. Approximately 72% of the dose was recovered by hemodialysis over a 4-hour period. The mean elimination half-life on dialysis was 1.21 ± 0.29 hours as compared with 42.4 ± 24.4 hours when off dialysis. Hepatic Impairment: A single intravenous dose of 0.1 mmol/kg of MultiHance was administered to 11 subjects (8 males and 3 females) with impaired liver function (Class B or C modified Child-Pugh Classification). Hepatic impairment had little effect on the pharmacokinetics of MultiHance with the parameters being similar to those calculated for healthy subjects. Gender, Age, Race: A multiple regression analysis performed using pooled data from several pharmacokinetic studies found no significant effect of sex upon the pharmacokinetics of gadobenate. Clearance appeared to decrease slightly with increasing age. Since variations due to age appeared marginal, dosage adjustment for geriatric population is not recommended. Pharmacokinetic differences due to race have not been systematically studied. Pediatric: A population pharmacokinetic analysis incorporated data from 25 healthy subjects (14 males and 11 females) and 15 subjects undergoing MR imaging of the central nervous system (7 males and 8 females) between ages of 2 and 16 years. The subjects received a single intravenous dose of 0.1 mmol/kg of MultiHance. The geometric mean C max was 62.3 μg/mL (n=16) in children 2 to 5 years of age, and 64.2 μg/mL (n=24) in children older than 5 years. The geometric mean AUC 0-∞ was 77.9 μg-h/mL in children 2-5 years of age (n=16) and 82.6 μg-h/mL in children older than 5 years (n=24). The geometric mean half-life was 1.2 hours in children 2 to 5 years of age and 0.93 hours in children older than 5 years. There was no significant gender-related difference in the pharmacokinetic parameters in the pediatric patients. Over 80% of the dose was recovered in urine after 24 hours."],"pregnancy":["8.1 Pregnancy Pregnancy Category C. MultiHance has been shown to be teratogenic in rabbits when given intravenously administered at 2 mmol/kg/day (6 times the human dose based on body surface area) during organogenesis (day 6 to 18) inducing microphthalmia/small eye and/or focal retinal fold in 3 fetuses from 3 separate litters. In addition, MultiHance intravenously administered at 3 mmol/kg/day (10 times the human dose based on body surface area) has been shown to increase intrauterine deaths in rabbits. There was no evidence that MultiHance induced teratogenic effects in rats at doses up to 2 mmol/kg/day (3 times the human dose based on body surface area), however, rat dams exhibited no systemic toxicity at this dose. There were no adverse effects on the birth, survival, growth, development and fertility of the F1 generation at doses up to 2 mmol/kg in a rat peri- and post-natal (Segment III) study. There are no adequate and well-controlled studies in pregnant women. MultiHance should be used during pregnancy only if potential benefit justifies the potential risk to the fetus."],"recent_major_changes":["Indications and Usage (Pediatrics) (1) 03/2010 Warnings and Precautions (5.1) 10/2009"],"recent_major_changes_table":["
Indications and Usage (Pediatrics) (1) 03/2010
Warnings and Precautions (5.1) 10/2009
"],"set_id":"e56fd303-9e0c-490b-8f31-64fc267b4df5","spl_product_data_elements":["MultiHance gadobenate dimeglumine gadobenate dimeglumine GADOLINIUM CATION (3+)"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Pregnancy Category C. MultiHance has been shown to be teratogenic in rabbits when given intravenously administered at 2 mmol/kg/day (6 times the human dose based on body surface area) during organogenesis (day 6 to 18) inducing microphthalmia/small eye and/or focal retinal fold in 3 fetuses from 3 separate litters. In addition, MultiHance intravenously administered at 3 mmol/kg/day (10 times the human dose based on body surface area) has been shown to increase intrauterine deaths in rabbits. There was no evidence that MultiHance induced teratogenic effects in rats at doses up to 2 mmol/kg/day (3 times the human dose based on body surface area), however, rat dams exhibited no systemic toxicity at this dose. There were no adverse effects on the birth, survival, growth, development and fertility of the F1 generation at doses up to 2 mmol/kg in a rat peri- and post-natal (Segment III) study. There are no adequate and well-controlled studies in pregnant women. MultiHance should be used during pregnancy only if potential benefit justifies the potential risk to the fetus. 8.3 Nursing Mothers It is not known to what extent gadobenate dimeglumine is excreted in human milk. It is known from rat experiments that less than 0.5% of the administered dose is transferred via milk from mother to neonates. Breast-feeding should be discontinued prior to the administration of MultiHance and should not be restarted until at least 24 hours after the administration of MultiHance. 8.4 Pediatric Use A total of 217 pediatric subjects (93% of subjects aged 2 years and above) were studied in clinical trials. No overall differences in safety or effectiveness were observed between these pediatric subjects and the adult subjects. The safety and efficacy of MultiHance in neonates and infants (ages 0-2 years) have not been established. The risk of NSF related to gadolinium may be increased in these patients due to their immature kidney function. 8.5 Geriatric Use Of the total number of 2982 adult subjects in clinical studies of MultiHance, 27% were 65 and over. No overall differences in safety or effectiveness were observed between these elderly subjects and the younger subjects. The drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to MultiHance may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function it may be useful to monitor renal function."],"version":"5","warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Hypersensitivity: anaphylactic/anaphylactoid reactions with cardiovascular, respiratory and cutaneous manifestations, ranging from mild to severe reactions including shock can occur. Monitor patients closely for need of emergency cardiorespiratory support. (5.1) Nephrogenic Systemic Fibrosis may occur in patients with severe renal insufficiency. (5.2) 5.1 Hypersensitivity Reactions Anaphylactic and anaphylactoid reactions have been reported, involving cardiovascular, respiratory, and/or cutaneous manifestations. Some patients experienced circulatory collapse and died. In most cases, initial symptoms occurred within minutes of MultiHance administration and resolved with prompt emergency treatment. Prior to MultiHance administration, ensure the availability of personnel trained and medications to treat hypersensitivity reactions. Additionally, consider the risk for hypersensitivity reactions, especially in patients with a history of hypersensitivity reactions or a history of asthma or other allergic disorders. Observe patients for signs and symptoms of a hypersensitivity reaction during and for up to 2 hours after MultiHance administration. 5.2 Nephrogenic Systemic Fibrosis Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate <30 mL/min/1.73 m 2 ) and in patients with acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period. In these patients, avoid use of gadolinium-based contrast agents unless the diagnostic information is essential and not available with non-contrast MRI. For patients receiving hemodialysis, physicians may consider the prompt initiation of hemodialysis following the administration of a gadolinium-based contrast agent in order to enhance the contrast agent’s elimination. The usefulness of hemodialysis in the prevention of NSF is unknown. Among the factors that may increase the risk for NSF are repeated or higher than recommended doses of a gadolinium-based contrast agent and the degree of renal function impairment at the time of exposure. Post-marketing reports have identified the development of NSF following single and multiple administrations of gadolinium-based contrast agents. These reports have not always identified a specific agent. Where a specific agent was identified, the most commonly reported agent was gadodiamide (Omniscan™), followed by gadopentetate dimeglumine (Magnevist ® ) and gadoversetamide (OptiMARK ® ). NSF has also developed following sequential administrations of gadodiamide with gadobenate dimeglumine (MultiHance ® ) or gadoteridol (ProHance ® ). The number of post-marketing reports is subject to change over time and may not reflect the true proportion of cases associated with any specific gadolinium-based contrast agent. The extent of risk for NSF following exposure to any specific gadolinium-based contrast agent is unknown and may vary among the agents. Published reports are limited and predominantly estimate NSF risks with gadodiamide. In one retrospective study of 370 patients with severe renal insufficiency who received gadodiamide, the estimated risk for development of NSF was 4% (J Am Soc Nephrol 2006; 17:2359). The risk, if any, for the development of NSF among patients with mild to moderate renal insufficiency or normal renal function is unknown. Screen all patients for renal dysfunction by obtaining a history and/or laboratory tests. When administering a gadolinium-based contrast agent, do not exceed the recommended dose and allow a sufficient period of time for elimination of the agent prior to any readministration [ see Dosage and Administration (2) and Clinical Pharmacology (12) ]. 5.3 Acute Renal Failure In patients with renal insufficiency, acute renal failure requiring dialysis or worsening renal function have occurred with the use of gadolinium-based contrast agents. The risk of renal failure may increase with increasing dose of the contrast agent. Screen all patients for renal dysfunction by obtaining a history and/or laboratory tests. Consider follow-up renal function assessments for patients with a history of renal dysfunction. 5.4 Extravasation and Injection Site Reactions Extravasation of MultiHance may lead to injection site reactions, characterized by local pain or burning sensation, swelling, blistering, and necrosis. In animal experiments, local reactions including eschar and necrosis were noted even on Day 8 post perivenous injection of MultiHance. Exercise caution to avoid local extravasation during intravenous administration of MultiHance. If extravasation occurs, evaluate and treat as necessary if local reactions develop. 5.5 Cardiac Arrhythmias Cardiac arrhythmias have been observed in patients receiving MultiHance in clinical trials [ see Adverse Reactions (6.1) ]. Assess patients for underlying conditions or medications that predispose to arrhythmias. A double-blind, placebo-controlled, 24-hour post dose continuous monitoring, crossover study in 47 subjects evaluated the effect of 0.2 mmol/kg MultiHance on ECG intervals, including QTc. The average changes in QTc values compared with placebo were minimal (< 5 msec). QTc prolongation between 30 and 60 msec were noted in 20 subjects who received MultiHance vs. 11 subjects who received placebo. Prolongations ≥ 61 msec were noted in 6 subjects who received MultiHance and in 3 subjects who received placebo. None of these subjects had associated malignant arrhythmias. The effects on QTc by MultiHance dose, other drugs, and medical conditions were not systematically studied. 5.6 Interference with Visualization of Certain Lesions Certain lesions seen on non-contrast images may not be seen on contrast- images. Exercise caution when interpreting contrast MR images in the absence of companion non-contrast MR images."]}